{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:55:22Z","timestamp":1788324922661,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcyt.2025.102014","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:17:33Z","timestamp":1764202653000},"page":"102014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3754-6121","authenticated-orcid":false,"given":"Krissada","family":"Natungnuy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-1967","authenticated-orcid":false,"given":"Piriya","family":"Luangwattananun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-9055","authenticated-orcid":false,"given":"Kamonlapat","family":"Supimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-5079","authenticated-orcid":false,"given":"Pornpimon","family":"Yuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8255-2201","authenticated-orcid":false,"given":"Punchita","family":"Rujirachaivej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-8031","authenticated-orcid":false,"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102014_bib0001","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.3390\/curroncol30050334","article-title":"Management of multiple myeloma: a review for general practitioners in oncology","volume":"30","author":"Monteith","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1027385","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"13","author":"Boussi","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.jcyt.2025.102014_bib0003","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-025-01675-5","article-title":"BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting","volume":"18","author":"Zheng","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0005","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2025.102014_bib0006","first-page":"119","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.jcyt.2025.102014_bib0007","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"key":"10.1016\/j.jcyt.2025.102014_bib0008","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/asheducation-2016.1.528","article-title":"Checkpoint inhibition in myeloma","volume":"2016","author":"Benson","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jcyt.2025.102014_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153114","article-title":"Immune checkpoint inhibitors in multiple myeloma: a review of the literature","volume":"216","author":"Caserta","year":"2020","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jcyt.2025.102014_bib0010","article-title":"To kill a cancer: targeting the immune inhibitory checkpoint molecule, B7-H3","volume":"1877","author":"Kanchan","year":"2022","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcyt.2025.102014_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jcyt.2025.102014_bib0012","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.102014_bib0013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.10.026","article-title":"LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma","volume":"117","author":"Gao","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0014","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.trecan.2024.06.002","article-title":"Targeting cancer stem cells in multiple myeloma","volume":"10","author":"Gunes","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jcyt.2025.102014_bib0015","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.102014_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08830185.2022.2102619","article-title":"B7-H3-targeted CAR-T cell therapy for solid tumors","volume":"41","author":"Li","year":"2022","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123081","article-title":"CD28 and 41BB costimulatory domains alone or in combination differentially influence cell surface dynamics and organization of chimeric antigen receptors and early activation of CAR T cells","volume":"15","author":"Mez\u0151si-Csapl\u00e1r","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2025.102014_bib0018","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"issue":"16_Suppl","key":"10.1016\/j.jcyt.2025.102014_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10011","article-title":"STRIVE-02: a first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed\/refractory solid tumors","volume":"40","author":"Pinto","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0020","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2025.102014_bib0021","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2025.102014_bib0022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-020-06032-3","article-title":"Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy","volume":"186","author":"Luangwattananun","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jcyt.2025.102014_bib0023","doi-asserted-by":"crossref","first-page":"657868","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107069","article-title":"Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells","volume":"89","author":"Sangsuwannukul","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0025","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2025.102014_bib0026","doi-asserted-by":"crossref","first-page":"802876","DOI":"10.3389\/fonc.2021.802876","article-title":"Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains","volume":"11","author":"Wutti-In","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0027","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00262-018-2212-2","article-title":"Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells","volume":"67","author":"Panya","year":"2018","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.jcyt.2025.102014_bib0028","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1472-6750-13-98","article-title":"Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells","volume":"13","author":"Cribbs","year":"2013","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0029","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jcyt.2025.102014_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcyt.2025.102014_bib0031","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102014_bib0032","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"Suppl. 1","key":"10.1016\/j.jcyt.2025.102014_bib0033","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1182\/blood-2022-162566","article-title":"B7-H3 trike enhances killing of myeloid derived suppressor cells in multiple myeloma","volume":"140","author":"Merino","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102014_bib0034","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/vaccines11020313","article-title":"CAR-T cells with phytohemagglutinin (PHA) provide anti-cancer capacity with better proliferation, rejuvenated effector memory, and reduced exhausted T cell frequencies","volume":"11","author":"Gulden","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jcyt.2025.102014_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front Immunol"},{"issue":"5, Suppl","key":"10.1016\/j.jcyt.2025.102014_bib0036","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jcyt.2019.03.348","article-title":"Glucose deprivation enriches for central memory T cells during chimeric antigen receptor-T cell expansion","volume":"21","author":"Amini","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.102014_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1321596","article-title":"Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges","volume":"14","author":"Harrer","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0038","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.102014_bib0039","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0040","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00262-020-02838-8","article-title":"CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.jcyt.2025.102014_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1063454","article-title":"Analysis of causes for poor persistence of CAR-T cell therapy in vivo","volume":"14","author":"Kong","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2025.101632","article-title":"Research progress of targeted BCMA CAR-T therapy for relapsed\/refractory multiple myeloma antigen-negative relapse","volume":"38","author":"Kong","year":"2025","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0043","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/2326-6066.CIR-19-0908","article-title":"Excessive costimulation leads to dysfunction of adoptively transferred T cells","volume":"8","author":"Wijewarnasuriya","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2025.102014_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcyt.2025.102014_bib0045","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability","volume":"130","author":"Guedan","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2025.102014_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0047","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1684127","article-title":"B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models","volume":"9","author":"Huang","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2025.102014_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109442","article-title":"Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition","volume":"113","author":"Yuti","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jcyt.2025.102014_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcyt.2025.102014_bib0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.33192\/smj.v76i5.268031","article-title":"Cancer immunotherapy: challenges and advancements in CAR T cell technology","volume":"76","author":"Yenchitsomanus","year":"2024","journal-title":"Siriraj Med J"},{"key":"10.1016\/j.jcyt.2025.102014_bib0051","article-title":"PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:19:59Z","timestamp":1780816799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925009107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1465324925009107"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102014","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102014"}}